Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid
Pitchayajittipong, C., Shur, J. and Price, R., 2009. Engineering of crystalline combination inhalation particles of a long-acting β2-agonist and a corticosteroid. Pharmaceutical Research, 26 (12), pp. 2657-2666.
Related documents:This repository does not currently have the full-text of this item.
You may be able to access a copy if URLs are provided below. (Contact Author)
Purpose: Engineering of inhalation particles incorporating, in each individual particle, a combination of a long-acting β-agonist and a glucocorticosteroid in a pre-determined and constant ratio for delivery via a dry powder inhaler (DPI). Methods: Individual crystalline particles containing both the glucocorticosteroid fluticasone propionate (FP) and long-acting β-agonist salmeterol (SX) were prepared, in a ratio of 10:1, using the solution atomization and crystallization by sonication (SAX) process. Combination drug particles were characterized by particle size, morphology, crystallinity and aerosolisation efficiency using inertial impaction. Results: Combination drug particles were spherical and crystalline, with a median diameter of 4.68 ± 0.01 μm. Aerosolisation of formulations containing combination drug particles resulted in greater uniformity in delivery ratios of both actives across all stages of the impactor before and after storage. Conclusions: Actives in a pre-determined dose ratio can be crystallised in a single particle using the SAX process.
|Creators||Pitchayajittipong, C., Shur, J. and Price, R.|
|Departments||Faculty of Science > Pharmacy & Pharmacology|
Actions (login required)